1. 518. Model-informed Dose Selection of Dual Toll-like Receptor 7/8 Inhibitor Enpatoran (M5049) for the Treatment of COVID-19 Pneumonia. (4th December 2021) Authors: Klopp-Schulze, Lena; Shaw, Jamie; Dong, Jennifer; Khandelwal, Akash; Adams, Elizabeth; Yu, Dongzi; Goteti, Kosalaram Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Applying Modeling and Simulations for Rational Dose Selection of Novel Toll‐Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need. Issue 2 (21st May 2022) Authors: Klopp‐Schulze, Lena; Shaw, Jamie V.; Dong, Jennifer Q.; Khandelwal, Akash; Vazquez‐Mateo, Cristina; Goteti, Kosalaram Journal: Clinical pharmacology & therapeutics Issue: Volume 112:Issue 2(2022) Page Start: 297 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. Issue 3 (18th November 2019) Authors: Novakovic, Ana M.; Wilkins, Justin J.; Dai, Haiqing; Wade, Janet R.; Neuteboom, Berend; Brar, Satjit; Bello, Carlo L.; Girard, Pascal; Khandelwal, Akash Journal: Clinical pharmacology & therapeutics Issue: Volume 107:Issue 3(2020) Page Start: 588 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Model‐informed drug development supporting the approval of the avelumab flat‐dose regimen in patients with advanced renal cell carcinoma. (27th February 2022) Authors: Masters, Joanna C.; Khandelwal, Akash; di Pietro, Alessandra; Dai, Haiqing; Brar, Satjit Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 11:Number 4(2022) Page Start: 458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab. (19th January 2022) Authors: Terranova, Nadia; French, Jonathan; Dai, Haiqing; Wiens, Matthew; Khandelwal, Akash; Ruiz‐Garcia, Ana; Manitz, Juliane; von Heydebreck, Anja; Ruisi, Mary; Chin, Kevin; Girard, Pascal; Venkatakrishnan, Karthik Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 11:Number 3(2022) Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Pharmacometrics Golems: Exposure‐Response Models in Oncology. Issue 5 (14th March 2022) Authors: Khandelwal, Akash; Grisic, Ana‐Marija; French, Jonathan; Venkatakrishnan, Karthik Journal: Clinical pharmacology & therapeutics Issue: Volume 112:Issue 5(2022) Page Start: 941 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Rabies encephalitis. Issue 4 (26th April 2021) Authors: Chaudhary, Shyam Chand; Khandelwal, Akash; Tandon, Ruchika; Sawlani, Kamal Kumar Journal: BMJ case reports Issue: Volume 14:Issue 4(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. Issue 12 (December 2021) Authors: McCarthy, James S; Yalkinoglu, Özkan; Odedra, Anand; Webster, Rebecca; Oeuvray, Claude; Tappert, Aliona; Bezuidenhout, Deon; Giddins, Marla J; Dhingra, Satish K; Fidock, David A; Marquart, Louise; Webb, Lachlan; Yin, Xiaoyan; Khandelwal, Akash; Bagchus, Wilhelmina M Journal: Lancet infectious diseases Issue: Volume 21:Issue 12(2021) Page Start: 1713 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1. Issue 3 (3rd March 2020) Authors: Vugmeyster, Yulia; Wilkins, Justin; Koenig, Andre; El Bawab, Samer; Dussault, Isabelle; Ojalvo, Laureen S.; De Banerjee, Samrita; Klopp‐Schulze, Lena; Khandelwal, Akash Journal: Clinical pharmacology & therapeutics Issue: Volume 108:Issue 3(2020) Page Start: 566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study. (9th October 2020) Authors: Grisic, Ana‐Marija; Khandelwal, Akash; Bertolino, Mauro; Huisinga, Wilhelm; Girard, Pascal; Kloft, Charlotte Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 9:Number 11(2020) Page Start: 628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗